Table 2.
Glutaminase (GLS1) immunohistochemistry protein expression and clinicopathological parameters of prostate adenocarcinoma cases in TMA cohort.
| Variables | GLS1 Score | p-Value | |||
|---|---|---|---|---|---|
| High Expression (n = 38) |
Low Expression (n = 32) |
No (n = 79) |
Missing (n = 5) |
||
| Age | 0.29 | ||||
| <60 | 20 (24%) | 17 (20%) | 47 (56%) | ||
| ≥60 | 18 (28%) | 15 (23%) | 32 (49%) | ||
| Race | 0.3 | ||||
| White | 33 (86.8%) | 27 (84.4%) | 57 (72.2%) | 4 | |
| Black | 5 (13.2%) | 5 (15.6%) | 20 (25.3%) | 1 | |
| Other | 0 | 0 | 2 (2.5%) | ||
| pT stage | 0.6 | ||||
| pT2 | 19 (50%) | 18 (56.3%) | 40 (51.3%) | 4 | |
| pT3 | 19 (50%) | 12 (37.5%) | 34 (43.6%) | 1 | |
| pT4 | 0 | 2 (6.3%) | 4 (5.1%) | 0 | |
| Missing | 0 | 0 | 1 | ||
| pN | 0.2 | ||||
| Yes | 1 (2.9%) | 0 | 5 (7.9%) | 1 | |
| No | 34 (97.1%) | 29 (100%) | 58 (92.1%) | 3 | |
| Gleason Grade Group | 0.5 | ||||
| 1 | 9 (23.6%) | 6 (18%) | 5 (6.3%) | 1 | |
| 2 | 16 (42%) | 11 (34%) | 37 (46.8%) | 1 | |
| 3 | 4 (10.5%) | 6 (18.7%) | 18 (22.8) | 1 | |
| 4 | 3 (7.8%) | 1 (3%) | 4 (5%) | ||
| 5 | 5 (13%) | 5 (15.6%) | 11(13.9%) | ||
| Unknown | 1(2.6%) | 3 (9.3%) | 4 (5%) | 2 | |
| Smoking | 0.9 | ||||
| Yes | 12 (31.6%) | 13 (40.6%) | 28 (35.4%) | 3 | |
| No | 13 (34.2%) | 10 (31.3%) | 27 (34.2%) | 0 | |
| Unknown | 13 (34.2%) | 9 (28.1%) | 24 (30.4%) | 2 | |
pT = pathological stage, pN = pathological node.